Correlation Between Eyenovia and Citius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eyenovia and Citius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyenovia and Citius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eyenovia and Citius Pharmaceuticals, you can compare the effects of market volatilities on Eyenovia and Citius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyenovia with a short position of Citius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyenovia and Citius Pharmaceuticals.

Diversification Opportunities for Eyenovia and Citius Pharmaceuticals

0.81
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Eyenovia and Citius is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Eyenovia and Citius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citius Pharmaceuticals and Eyenovia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyenovia are associated (or correlated) with Citius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citius Pharmaceuticals has no effect on the direction of Eyenovia i.e., Eyenovia and Citius Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eyenovia and Citius Pharmaceuticals

Given the investment horizon of 90 days Eyenovia is expected to under-perform the Citius Pharmaceuticals. In addition to that, Eyenovia is 1.41 times more volatile than Citius Pharmaceuticals. It trades about -0.25 of its total potential returns per unit of risk. Citius Pharmaceuticals is currently generating about -0.27 per unit of volatility. If you would invest  1,012  in Citius Pharmaceuticals on August 31, 2024 and sell it today you would lose (652.00) from holding Citius Pharmaceuticals or give up 64.43% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Eyenovia  vs.  Citius Pharmaceuticals

 Performance 
       Timeline  
Eyenovia 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eyenovia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Citius Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Citius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Eyenovia and Citius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eyenovia and Citius Pharmaceuticals

The main advantage of trading using opposite Eyenovia and Citius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyenovia position performs unexpectedly, Citius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will offset losses from the drop in Citius Pharmaceuticals' long position.
The idea behind Eyenovia and Citius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes